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A RETROSPECTIVE ASSESSMENT OF ROUTINE RENAL FUNCTION 
SCREENING IN PATIENTS WITH SICKLE CELL DISEASE  
JUSTIN PAUL KITTREDGE 
ABSTRACT 
 
BACKGROUND 
Routine renal screens are essential to the healthcare maintenance of pediatric patients 
with sickle cell disease. There is an inadequate amount of evidence, however, to support 
a universal standardized practice. As a result, sickle cell patients are subject to significant 
variability in care. The objective of this study was to assess the practice of routine renal 
screens at Boston Children’s Hospital.  
METHODS 
We performed a chart review of 330 total patients from 2011 through 2013 to analyze the 
performance of microalbumin renal screens and urinalyses at routine clinic visits. With 
this data, we evaluated the institution’s compliance with its adopted renal screening 
guidelines, examined renal screening variability across patient demographics and among 
providers, and compared the performance of different laboratory measures. 
RESULTS 
Renal screens were performed in 34.2% of the eligible study population. There were no 
statistically significant differences in the performance of renal screens across patient age, 
sickle phenotype or disease-modifying therapy. Patients aged from 5-9 years old, 
however, demonstrated a non-significant trend toward a lower frequency of successful 
  vi 
renal screens. The percentage of samples collected for microalbumin excretion within the 
female cohort was significantly higher than the institutional average (41.7% vs 34.2%, p 
= 0.024) and significantly lower within the male population (27.6% vs 34.2%, p = 0.034). 
The performance of renal screens varied significantly from one provider to another. In all 
areas of analysis, the frequency of urinalyses performed was similar to the frequency of 
microalbumin excretion rates.  
CONCLUSION  
This study suggests that providers are not routinely adhering to the institutional standard 
for renal screens. There remains little insight into providers’ basis of renal screen 
practice: providers may not be cognizant of the institution’s practice guidelines or may 
not consider early detection of microalbuminuria essential to the healthcare maintenance 
in patients with sickle cell disease. Future studies are warranted to fully comprehend the 
low frequency of renal screens performed in pediatric sickle cell patients.     
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INTRODUCTION 
 
Sickle cell disease (SCD) describes a group of autosomal recessive disorders that 
are caused by point mutations in the sixth codon of the β-globin gene. In the most 
common anomaly, hydrophilic glutamic acid is replaced with hydrophobic valine, 
resulting in the formation of sickle hemoglobin (HbS) (Figures 1 and 2). There are 
multiple combinations of abnormal hemoglobins resulting in SCD phenotypes. All 
contain at least one sickle gene (HbS). Inheritance of the sickle gene from both parents 
leads to the homozygous HbSS disease, otherwise known as Sickle Cell Anemia (SCA). 
In addition to SCA, there are three other common heterozygote phenotypes linked to 
SCD, all with variable clinical severity (Table 1). The sickle cell gene has profound 
impacts on the red blood cell (RBC) and the patient’s overall well-being. Hemoglobin is 
the protein in the RBC responsible for transporting oxygen from the lungs to the rest of 
the body. High concentrations of HbS polymerize when oxygen is released, causing 
sickling in the RBC. Normally pliable and biconcave-shaped RBCs become rigid and 
sickle shaped (Figure 3). This results in increased red cell hemolysis, adhesion of sickled 
cells to vascular endothelium, and thus occlusion of small vasculature that impairs blood 
supply and function of multiple organs (Figure 4). 
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Figure 1. Hb-Beta mutation. A single 
point mutation in the 147 amino acid 
polypeptide chain of Hb-Beta results in 
the formation of HbS (1).  
Figure 2: Abnormal SCD Hemoglobin 
HbS. Abnormal hydrophobic patch at the 
site of the 6-valine replacement is shown as 
projection in bottom left corner of HbS (1).  
Figure 3. Polymerization of HbS. Deoxygenation 
of HbS causes a conformational change that allows 
interaction with other deoxygenated HbS 
hydrophobic regions, resulting in the formation of 
a 14 stranded helical fiber (2).  
Figure 4. Sickle cell vasoocclusion. As 
deoxy HbS polymerizes and fibers align, 
the red cell is distorted into the rigid 
“sickle” shape, leading to vasoocclusion 
and other complications (3).  
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Phenotype Clinical Syndrome 
HbSS (SCA) Severe or moderately severe 
HbS/β0 (Beta-Zero) Thalassemia    Severe or moderately severe (often 
indistinguishable from HbSS) 
HbSC Intermediate severity 
Hb/β+ (Beta-Plus) Thalassemia Mild to moderately severe (variable in 
different ethnic groups) 
Table 1. SCD Phenotype and Clinical Severity. The frequency and severity of clinical 
complications varies between SCD phenotypes. Symptoms are generally more severe in 
HbSS and HbS Beta-Zero Thalassemia and milder in HbSC and HbS Beta-Plus 
Thalassemia (4).  
 
While the clinical course of SCD is remarkably unpredictable, the kidneys are 
especially sensitive to chronic sickling. This is not surprising, given the extremely high 
oxygen consumption by these organs and their innumerable small blood vessels. Though 
the kidneys make up less than 1% of total body mass, they receive approximately 25% of 
the total cardiac output (5). Furthermore, the renal medulla’s naturally hypoxic, hyper-
osmolar and acidic environment promotes RBC sickling within its network of 
microvasculature. A number of kidney disorders heralded by SCD, collectively referred 
to as sickle cell nephropathy (SCN), develop as a result of recurrent renal vassoocclusion, 
ischemia-reperfusion injury, and loss of nephron mass with compensatory glomerular 
hypertrophy. These renal disorders include hyposthenuria, hematuria, tubular 
acidification, hyperfiltration and proteinuria (6). Persistent injury from SCN can progress 
to Chronic Kidney Disease (CKD) and eventually End Stage Renal Disease (ESRD) 
(Table 2). A patient with ESRD cannot survive without dialysis or a kidney transplant.   
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Stage  Glomerular Filtration Rate (GFR) Parameters 
Stage 1  Kidney damage with normal or increased GFR (≥ 90mL/min/1.73m2) 
Stage 2  Kidney damage with mildly decreased GFR (60-89 mL/min/1.73m2) 
Stage 3 Moderately decreased GFR (30-59 mL/min/1.73m2) 
Stage 4 Severely decreased GFR (15-29 mL/min/1.73m2) 
Stage 5 Kidney failure (ESRD); GFR < 15 mL/min/1.73m2 or on dialysis 
Table 2. Stages of Kidney Disease. CKD is defined as either kidney damage or a GFR 
<60 mL/min/1.73m2 for equal to or greater than 3 months. Kidney damage is defined as 
pathologic abnormalities or markers of damage, including in blood or urine tests or 
imaging studies (7). 
 
The earliest and most common renal complication in people with SCD is often 
hyposthenuria. Hyposthenuria describes the inability of the kidneys to concentrate urine 
when the kidneys’ countercurrent exchange mechanism is interrupted by the loss of deep 
juxtamedullary nephrons due to vasoocclusion within the vasa recta; the long straight 
capillaries that extend into the medulla of the kidney and lie parallel to the Loop of Henle 
(Figure 5) (8). Hyposthenuria first becomes evident in early childhood, causing frequent 
urination and even nocturnal enuresis. A study of 213 individuals with SCA revealed that 
42% of children from ages 6-8 and 9% of adults from ages 18-20 experienced involuntary 
voiding during sleep (10). Individuals with SCD and hyposthenuria are also at a higher 
risk for intravascular volume depletion, as they cannot properly respond to decreased oral 
fluid intake (8).  
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Figure 5: Juxtamedullary Nephron. Cross section of the kidney at the cortex and 
medulla border shows a normal juxtamedullary nephron that is damaged by 
vasoocclusion, leading to hyposthenuria (9). 
 
Hematuria, or the presence of blood in the urine, is also a common manifestation 
of renal dysfunction in individuals with SCD. This condition is most often secondary to 
renal papillary necrosis caused by medullary infarction from obstruction of the vessels 
supplying the vasa recta. Sloughing of the renal papillae as a result of papillary necrosis 
can occasionally obstruct urine outflow, causing infection and, sometimes, acute renal 
failure (11). Excretion urography in individuals with SCD revealed a 23% prevalence of 
papillary necrosis and related hematuria in adult patients with SCA (12). SCD also 
commonly damages the distal tubule of the nephron, leading to hyperkalemia or an 
elevated concentration of the electrolyte potassium in the blood, as evidenced in various 
forms of renal tubular acidosis. Though the pathophysiologic mechanism is not 
completely understood, it is believed SCD renal damage causes the distal tubules to 
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become unresponsive to aldosterone. As a result, potassium excretion is inhibited and the 
pH of the blood is ultimately lowered (13).  
 While hyposthenuria, hematuria and renal tubular acidosis may arise from SCN, 
there is no evidence linking these disorders to progressive renal disease. They do not 
necessarily reflect decreased function in other areas of the kidney and cannot be 
considered early predictors of significant renal damage. On the other hand, the abnormal 
presence of albumin in the urine, or albuminuria, is widely considered to be the most 
accurate predictor of renal damage in individuals with SCD. Produced in the liver, 
albumin is one of the most abundant proteins in the blood. It is the first protein to leak 
into the urine when there is damage to the glomerulus, which normally functions as a 
filter, only allowing small positively charged waste molecules to pass from the blood into 
the urine (Figure 6). Microalbuminuria is defined by a urinary albumin excretion rate 
between 30 to 299 mg over 24 hours.  With progressive renal damage, kidney function 
declines over time and the concentration of albumin in the urine increases. A urinary 
albumin excretion rate that is between 300 and 3,500 mg per 24 hours is called 
macroalbuminuria and is largely irreversible despite medical intervention (15-16). When 
there is enough damage to the glomeruli to cause macroalbuminuria, other proteins such 
as low molecular weight immunoglobins, lysozyme, insulin, and beta-2 microglobulin are 
often found in the urine as well (17). The abnormal level of any proteins in the urine, 
which may or may not include albumin, is referred to as proteinuria. 
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Figure 6. Renal filtration. Blood from the afferent arteriole is filtered in the glomerulus 
before returning to circulation via the efferent arteriole. When damaged, the glomerulus 
allows larger proteins in the blood to pass into Bowman’s capsule, which is eventually 
excreted in urine (14).  
 
 
The presence of protein in the urine of SCD patients is mediated initially by 
hyperfiltration, suggesting that the total renal blood flow (RBF), and consequently GFR, 
is increased from a young age in affected individuals. This is not the case in normal 
individuals, where a decrease in GFR is typically the first indication of sustained damage 
to the kidneys. Though the mechanisms behind this phenomenon are poorly understood, 
it has been suggested that RBF and GFR are initially increased in individuals with SCD 
as a result of the secretion of medullary vasodilator prostaglandins in response to the 
damage caused by increased renal hypoxia (18). Hyperfiltration leads to glomerular 
hypertension and hypertrophy, the sequelae of which is glomerulosclerosis, or scarring of 
the glomeruli. The abnormal anatomical changes brought on by this scarring result in 
functional abnormalities, namely a marked increase in glomerular permeability that leads 
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to microalbuminuria and progresses to macroalbuminuria and eventually proteinuria (6). 
Hyperfiltration begins to disappear as SCN progresses. In the prospective BABY HUG 
trial, GFR in infants with SCA was abnormally high, normalized into adulthood and 
declined further with age, suggesting that renal dysfunction in patients with SCA begins 
as early as infancy and progresses over time (19). Decreased GFRs is a common finding 
amongst SCD patients in their third or fourth decade of life. Unlike GFR, proteinuria 
increases in parallel with the progression of renal damage.  
 
Detecting Microalbuminuria as a Screening Tool for CKD 
While dipstick urinalysis (UA) is a common laboratory method used to screen for 
renal dysfunction, measuring microalbumin (MA) excretion rate by a specialized 
concentration assay is vastly preferred. Protein levels in the urine determined by UA are 
only semi-quantitative and cannot accurately measure the lower limits of 
microalbuminuria. MA excretion rates allow clinicians to detect renal dysfunction long 
before a positive protein result by UA or a decrease in GFR can be detected. Importantly, 
microalbuminuria from SCN can be detected in early childhood. Multiple studies in U.S. 
pediatric SCD have demonstrated a prevalence of microalbuminuria of 16-20% (20-22). 
The presence of albuminuria increases in parallel with age, as renal damage from SCD 
accumulates.  A 2006 chart review of 300 adults with SCD revealed that 68% of patients 
with hemoglobin SS and 32% of patients with all other sickle genotypes had some 
amount of albumin in their urine (23). Similar results were reported in a 2010 
investigation that explored the relationship between albuminuria and common laboratory 
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variables in individuals with SCD, where 33% of all adult subjects had microalbuminuria 
(24).  
Albuminuria and proteinuria are strongly correlated with risk for future 
progression to CKD, which impacts 4 to 18% of all SCD patients (25). In a long-term 
study of individuals with HbSS, the development of CKD was closely associated with the 
presence of proteinuria and increased age. Of the 369 study subjects, 78 developed 
proteinuria. In the sub-population that developed proteinuria, 22% progressed to CKD 
and 7% advanced to ESRD requiring chronic dialysis (26). Similar results were achieved 
in a follow-up study of 38 patients with SCD, where significant proteinuria or azotemia 
occurred in 4-20% of subjects (27). Studies of non-sickle patient populations also support 
the findings that proteinuria predicts long-term development of CKD and ESRD (28).  
By recognizing the beginning signs of SCN-induced CKD, early interventions can 
occur, resulting in better health outcomes and long-term savings in medical costs. The 
use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin type II receptor 
blockers (ARBs) reduce the degree of albumin in the urine in patients with diabetic and 
non-diabetic nephropathy and thus slow or, in some cases, halt decline in renal function. 
An independent review of 11 randomized, controlled trials investigating the efficacy of 
ACE inhibitors for patients with nondiabetic kidney disease by Jafar et al. found that 
lowering albuminuria was associated with better renal outcome (29). In patients with type 
2 diabetes and microalbuminuria, treatment with an ARB effectively prevented 
progression from micro- to macroalbuminuria (30). Falk et. al found that individuals with 
proteinuria treated with ACE inhibitors experienced a statistically significant reduction in 
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the degree of proteinuria and glomerular capillary hypertension (31). Hydroxyurea has 
also been shown to have a beneficial role in deterring renal damage in individuals with 
SCD, as it reduces sickling and thereby mitigates all organ damage. The prevalence of 
albuminuria among adult SCD patients at the University of Chapel Hill Kidney Center 
was lower among patients on hydroxyurea (34.7%) than those receiving no drug therapy 
(55.4%) (32).   
 
Screening for SCN During Routine Health Care Evaluations 
Over the past four decades, significant progress has been made in the treatment of 
SCD. The median life expectancy in the United States for individuals with SCA increased 
from less than 15 years in the 1970s to more than 40 years by the late 1990s (33). Today, 
many afflicted with the disease are even entering their sixth and seventh decades of life. 
The mortality rate in a cohort followed from 1999 through 2002 fell by 68% in SCD 
patients aged 0 through 3 years, 39% from age 4 through 9, and 24% from age 10 through 
14 when compared  to a cohort from 1983 through 1986 (34). This dramatic reduction in 
mortality can be attributed in part to the implementation of universal newborn screening, 
the introduction of prophylactic antibiotics and pneumococcal vaccinations, and parental 
education (35). Equally important, however, has been the growing emphasis on 
preventative medicine. Healthcare maintenance includes both the standard preventative 
care provided to all people and the specialized, interdisciplinary care that is unique to 
SCD and its multisystem clinical manifestations. One essential component of proper 
healthcare maintenance is the routine wellness examinations performed by hematologists 
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in large sickle cell centers. It is during these evaluations that providers regularly screen 
for complications of SCD, including renal dyfunction.   
While routine healthcare maintenance is essential to the general health and 
wellbeing of all SCD patients, there is no “gold” standard of practice for patients with 
SCD. There are few evidence-based studies which could guide routine healthcare 
maintenance for SCD. In response to the absence of a universal standard of care, 
numerous sickle cell associations, comprised of a handful of multidisciplinary experts, 
have published general consensus guidelines and specific indicators of quality care. 
These guidelines reveal both subtle and significant variations across the different groups 
of sickle cell experts.  
Within these guidelines, the topic of screening for renal function contained 
substantial inconsistencies, especially regarding the frequency, age limitations, and even 
the methods of detection (Table 3). Many of the groups defined age parameters vaguely. 
The New England Sickle Cell Consortium (NEPSCC) recommends renal screening in 
“older” children, while the University of South Alabama Comprehensive Sickle Cell 
Center does not indicate any age. While most groups advocate annual testing, the Sickle 
Cell Advisory Committee only ambiguously suggests “regular” UAs.  In an effort to 
develop a universal set of quality care indicators in the management of SCD, Wang et al. 
did not consider routine screening for renal damage as an essential performance measure 
in healthcare maintenance (36-43).    
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Expert Panel Recommendation 
New England Pediatric Sickle Cell Consortium 
(NEPSCC) 
Annually in “older” children 
Expert Panel Report of the NIH 2013 Annually beginning at age 10 
National Institute of Health: National Heart, 
Lung, and Blood Institute 
Annually beginning at ≥ 12 months 
Mid-Atlantic Sickle cell Disease Consortium 
(MASCC) 
Annually beginning at birth 
Sickle Cell Advisory Committee (SCAC) “Regular” UAs as part of health maintenance 
visit, no beginning age indicated 
Sickle Cell Disease Care Consortium (Texas 
Department of Health) 
Annually beginning at 2 years old 
University of South Alabama Comprehensive 
Sickle Cell Center 
Annually, no beginning age indicated 
Wang et al.  Screening for renal disease not considered a 
quality care indicator in routine health  
maintenance 
Table 3: SCD expert group guidelines. Table above highlights the differences among 
the different sickle cell associations and their routine renal screen recommendations (36-
43). 
 
This study focuses specifically on the Sickle Cell Disease Program at Boston 
Children’s Hospital (BCH), one of the largest in the northeast region. As a member of the 
NEPSCC, the program at BCH has adopted this consortium’s routine healthcare 
maintenance guidelines. As mentioned above, the NEPSCC recommends annual renal 
function screening in “older children.” Dr. Matthew Heeney, Director of the Sickle Cell 
Program at BCH and contributing member to the NEPSCC’s published guidelines, 
defined “older children” as pediatric patients capable of providing urine specimens on 
demand and without assistance, or about five years of age.  
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Study Objectives 
The primary objective of this thesis was to assess the practice of screening for renal 
disease at BCH’s Sickle Cell Disease Program during routine healthcare maintenance 
evaluations. The findings of this study will have important clinical implications, as it 
aimed to answer the following questions:   
 Does the institution follow the guidelines set forth by the NEPSCC? 
 Do screening practices differ across certain patient demographics? 
 Do screening practices differ across providers? 
 How did screening by MA excretion rate compare to the frequency of UAs 
performed? 
Secondary to the above objectives, this study hoped to encourage future dialogue and 
investigations that will address the following discussion points:  
 How are providers educated in the practice of routine renal screening? 
 What is the basis of practice (what are the physicians’ reasoning for performing 
routine renal screenings)? 
 Should a standard universal plan be instituted? 
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METHODS 
 
This investigation was a retrospective chart review of BCH patients diagnosed with SCD. 
 
Search Strategies 
A list of all SCD patients seen at the BCH SCD clinic from the years 2011 
through 2013 was generated by the administrative staff and maintained in a Microsoft 
Access database. The database contained names, demographics, and other identifying 
information for each patient. We then ran a query on Access to eliminate those patients 
who met the exclusion criteria and failed to meet the study inclusion criteria.   
Study population data was obtained through PowerChart, the electronic medical 
record platform utilized by BCH. Study subjects’ electronic medical records were 
accessed on an individual basis, drawing from the eligible patient list generated by 
Microsoft Access. Within PowerChart, data was obtained in hematology outpatient clinic 
notes and laboratory test results. Patients’ lab results were filtered to include only urine 
tests performed during the calendar years of 2011-2013. A MA excretion rate and UA 
were considered part of the comprehensive clinical visit if the lab date directly coincided 
with a date on which a comprehensive sickle cell clinic note was created.  
Patient laboratory results were accessed from PowerChart and cross-referenced 
with the dates of sickle cell clinic visits to determine how often UAs and MA excretion 
rates were ordered separately and in combination.  
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Study Population 
Patients were included in the study if they met all of the following criteria:  
 The patient was diagnosed with the sickle cell disease (HbSS, HbSC, HbS 
Beta-Plus Thalassemia, or HbS Beta-Zero Thalassemia) 
 The patient attended a routine clinic visit at BCH’s Comprehensive SCD 
Program at least once during the calendar years of 2011, 2012, or 2013 
 The patient was at least 5 years old or older at the time of their first 
comprehensive clinic visit of the year  
Patients were excluded from the study if they met any of the following criteria: 
 The patient was diagnosed with Sickle Cell Trait (HbAS) 
 The patient was under five years old at the time of a SCD clinic visit 
 The patient was receiving chronic transfusion therapy1 
 
Measures 
Institutional Compliance With NEPSCC Guidelines 
NEPSCC guidelines define a successful renal screen as the collection of a MA 
excretion rate, with or without a complete UA. All of the laboratory measurements on the 
urine specimens were performed at the clinical laboratory at BCH. The BCH clinical lab 
                                                        
1 Patients receiving chronic transfusion therapy were excluded from analysis of 
institutional variability across treatment regimens. The department practice is to have 
routine comprehensive visits twice annually unless a patient is on a disease modifying 
therapy, in which case they are seen approximately every 3 months. Patients receiving 
chronic transfusion therapy, however, are often seen by a wider variety of providers and 
at locations outside of the hematology clinic, making it difficult to discern exactly when 
renal screens were due. 
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estimates MA excretion rate by measuring the urine albumin-to-creatinine (UACR) ratio. 
Spot, or random, UACR tests accurately predict the 24-hour MA excretion rate (44). UA 
orders were also tracked, but were not considered a renal screening event. 
To determine whether or not the sickle cell program at BCH adhered to the 
NEPSCC guidelines, the frequency of successful renal screens performed within the 
study population was calculated. For each year from 2011 through 2013, every patient 
was determined to have either a successful renal screen or an unsuccessful renal screen. 
As most patients are seen at least twice annually, some patients had more than one MA 
excretion rate result within the same year. A single patient, however, could experience 
only one successful or unsuccessful event per year. Any additional MA results were not 
included in the compliance determination. The data for all three years was combined to 
determine the collective frequency of successful renal screens at BCH.  
The overall frequency of UA’s obtained within the entire study population was 
calculated in the manner described above.  
 
Renal Screen Variability Across Patient Demographics 
To determine variability in renal screening practices at BCH based on patient 
demographics, the study subjects were categorized into subpopulations based upon age, 
sex, sickle phenotype, and therapy. The overall frequency of successful renal screens for 
the subsets within each demographic category was determined by the same method 
described above in Institutional Compliance With NEPSCC Guidelines. 
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Variability in UA performance across patient demographics was determined in the 
same manner and compared to the frequency of MA orders.   
 
Renal Screen Variability by BCH Provider 
Study providers were defined as the hematology attending physicians responsible 
for the clinic visit. Interns, residents, fellows, nurse practitioners, and physician assistants 
who may have evaluated patients in clinic were excluded from the analysis of renal 
screening variability among providers.  
To determine the variability in renal screening performance among providers, an 
inventory of the total number of sickle cell clinic visits was created for each individual 
provider.  These clinic visits were classified as renal screen “due” and renal screen “not 
due.” A renal screen was “due” if the patient had not yet had a MA excretion rate 
collected during a routine sickle cell visit for the year in question. A visit in which a renal 
screen was “not due” was defined as any visit that occurred after a renal screen was 
performed earlier in the same calendar year. Analysis of provider variability was 
determined by the portion of MAs obtained relative to MAs due.  
Provider variability in UA orders was determined using the same method 
described above.  
 
Statistical Analysis 
Institutional Compliance 
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The Z-ratio between UA and MA frequency was computed using the VassarStats 
Computational Program (Poughkeepsie, NY) to find the significance of the difference 
between these two independent proportions at an alpha level of 5%. Using the 
VassarStats Computational program once again, the Z-ratio was defined for the 
proportion of MA and UAs collected separately. Those proportions were defined as: [(# 
of exclusive MAs performed) / (# of total MAs performed)] and [(# of exclusive UAs 
performed)  / (# of total UAs performed)]. The total number of MAs performed = 
(exclusive MAs) + (MA performed in conjunction with UA). The total number of UAs 
performed was calculated in the same manner. 
 
Variability Across Patient Demographics 
Lower-Tailed or Higher-Tailed Hypothesis Tests were used with a 5% 
significance (or alpha) level and a Z or T cirtical value to compare the frequency of 
successful renal screens for each demographic subset to the overall institutional 
frequency, also referred to as the institutional standard. 
 We used the VassarStats Computational program to compare the significance of 
the difference between UA and MA orders across each patient subset.  
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RESULTS 
 
 
Study Population  
 The subject selection screen yielded 330 patients who were eligible for analysis 
from 2011 through 2013. The analysis included 105 patients in 2011, 112 patients in 
2012, and 113 patients in 2013.  The demographics of the study population are 
represented in Table 4. The study population was evenly distributed by age group and 
sex. The HbSS sickle cell genotype accounted for a majority of the study population 
(84.8%). HbS Beta-Zero and HbS Beta-Plus were the only other sickle genotypes 
represented in the study. From 2011 through 2013, 56.4% of the total study population 
was being treated with hydroxyurea, 33% of the population received no disease-
modifying therapy, and 11% were receiving chronic transfusion therapy. 
 Of the study population, 29.1 % had one comprehensive sickle cell clinic 
appointment per calendar year from 2011 through 2013 (n = 96). During the study period, 
38.5% of the population had between 2 and 3 clinic visits per year (n = 127), while 32.4% 
visited the clinic 4 or more times per year (n = 107).  
 
Institutional Compliance with NEPSCC Guidelines 
 Of the 330 patients, 113 (or 34.2%) had an annual MA excretion rate measured 
during a comprehensive sickle cell visit. 
The frequency of UA’s performed at BCH was not significantly different than the 
rate of MA excretion rates collected (32.1% vs. 34.2%, p = .281).   
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The majority of MAs and UAs were performed together (Figure 7). While BCH 
providers performed more MAs alone than they did UAs, there was no significant 
difference between the amount of MAs and UAs performed alone (39 vs. 26, p=0.084).  
 
 
   
 
 
 
 
 
 
Figure 7. Comparison of MA excretion rates and UAs performed independently and 
in combination: 69% of all MA’s were performed in combination with a UA. 
77% of these UA’s were performed in combination with a MA excretion rate. 
 
Renal Screen Variability across Patient Demographics 
Renal screen variability was assessed for each demographic category (Table 
4).Compared to the institutional average (34.2%), the 5-9 year old group demonstrated a 
non-significant trend toward a lower frequency of successful renal screens during clinic 
visits. There was no statistically significant difference between the percentages of renal 
screens performed among the 10-14 year and 15 and older age groups and the 
institutional average. The percentage of MA excretion rates collected within the female 
MA only = 39 
MA+UA = 88 
UA only = 26 
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cohort was significantly higher than the institutional average (p = 0.024), whereas renal 
screens were performed significantly less often within the male population (p = 0.034)  
There was no significant difference between the frequency of renal screens among 
different sickle phenotypes or therapy cohort. 
 
Age Group % of Total 
Population 
% MA performed 
at least once 
p-value 
5-9 105/330 = 31.8% 30/105 = 28.6% 0.111 
10-14 108/330 = 32.7% 40/108 = 37% 0.271 
15+ 117/330 = 35.5% 43/117 = 36.8% 0.278 
Sex    
Female 156/330 = 47.3% 65/156 = 41.7% 0.024 
Male 174/330 = 52.7% 48/174 = 27.6% 0.034 
Phenotype    
HbSS 280/330 = 84.8% 96/280 = 34.3% 0.486 
HbS Beta-Zero 29/330 = 8.8% 7/29 = 24.1% 0.126 
HbS Beta-Plus 21/330 = 6.4% 10/21 = 47.6% 0.097 
Therapy    
Hydroxyurea 186/330 = 56.4% 69/186 = 37.1% 0.202 
None 109/330 = 33.0% 40/109 = 36.7% 0.293 
Table 4. Renal screen variability by patient demographics. Sex was the only patient 
variable category to show a statistically significant difference in renal screen performance 
compared to the institutional standard. Other variables, such as age and genotype showed 
pattern of differences, but were not large enough to be considered statistically significant.  
 
 
UA vs. MA in Variability Across Patient Demographics 
The frequency of UAs performed within each patient population subset was 
similar to the frequency of MAs performed within the same demographic category. We 
found no statistically significant difference within any population subset when comparing 
UA to MA renal screens (Table 5). 
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Age Group % UA performed at 
least once 
p-value (compared to 
% MA performed) 
5-9 35/105 = 33.3% 0.228 
10-14 36/108 = 33.3% 0.284 
15+ 35/117 = 29.9% 0.134 
Sex   
Female 60/156 = 38.5% 0.282 
Male 46/174 = 26.4% 0.405 
Phenotype   
HbSS 90/280 = 32.1% 0.295 
HbS Beta-Zero 5/29 = 17.2% 0.259 
HbS Beta-Plus 11/21 = 52.4% 0.379 
Therapy   
Hydroxyurea 63/186 = 33.9.1% 0.258 
None 39/109 = 35.87% 0.444 
Table 5. UA vs. MA performance across patient demographics. UAs were performed 
in near identical frequency to MAs across each patient demographic category.   
  
Renal Screen Variability among BCH Providers  
During the study period, 28 different BCH providers performed a total of 886 
comprehensive sickle cell evaluations on the collective study population. Provider P-10 
completed 549 (62%) of these examinations. Using the Extreme Studentized Deviate 
(ESD) test, we determined that this physician was a statistical outlier, and did not utilize 
this data in the analysis of renal screening variability among BCH providers.  
For the 27 remaining providers, renal screens were collectively considered “due” 
in 281 of the 337 sickle cell clinic evaluations. The frequency of obtaining a “due” renal 
screen varied significantly by provider (Figure 8).   
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Figure 8. Provider variability in performing renal screens at SCD visits. Half of the 
total providers in the study performed a renal screen when it was “due” at a SCD clinic 
visit between 9.4% and 42.5% of the time.  
 
There was significant variation in the number of routine sickle cell visits across 
providers (Figure 9). Provider P-06 had the most visits “due” for a renal screen (n = 56), 
while providers P-14 and P-20 both had the least number of visits “due” (n = 1). There 
was a general tendency across all providers not to collect urine specimens for MA 
excretion measurement in the majority of visits that were “due” for renal screens. The 
average number of clinic visits with a renal screen due was 10.4 per provider, while the 
providers collectively averaged 2.15 successful renal screens.   
 
0 20 40 60 80 100
Percentage
Percent of MA's Obtained When MA was Due at SCD 
Visit per Provider (2011-2013)
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Figure 9. MA excretion rates performed by provider. Each provider experienced a 
significant difference in the number of SCD clinic visits considered “due” for a renal 
screen. In general, providers failed to collect renal screens in a majority of these visits.  
 
UA vs. MA in Provider Variability 
 In general, individual providers successfully performed UAs at the relative same 
frequency as MAs. Only provider P-10 showed a significant difference (16 MAs vs. 5 
UAs). While still significant, there was less variability across providers in the 
performance of UAs compared to the performance of MAs. The providers collectively 
averaged 1.85 successful UA collections each (Figure 10).  
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Figure 10. UA performance compared to MA performance by provider. With the 
exception of Provider P-06, providers tended to perform UAs at a similar frequency as 
MAs. There was significant variability from one provider to another in the performance 
of UAs, though it was less than the variability across MAs.   
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DISCUSSION 
 
The aim of this study was to assess the practice of screening for renal function at 
BCH’s SCD Program during routine healthcare maintenance evaluations. As a 
department, BCH providers successfully obtained a renal function screening test in 34% 
of cases. BCH providers are more likely to order renal screens for female patients than 
male. Better designed studies might be necessary to more accurately assess if other 
patient variables, such as sickle phenotype, also influence the frequency of renal screens 
performed at BCH. The frequency of routine renal screens performed at the sickle cell 
clinic varies significantly from one provider to another. Finally, UAs are performed at a 
similar frequency as MA excretion rates. Although most UAs are collected in 
combination with MA excretion rates, a surprising number of UAs are collected alone. 
 While prior studies have emphasized the strong correlation between SCD and 
proteinuria, and its frequent progression to CKD (20-27), specific studies examining the 
process of screening for renal failure by MA detection in SCD patients have been 
lacking. Renal damage is a common and serious complication in SCD. The long-term, 
multi-center Cooperative Study of Sickle Cell Disease (CSSCD) identified renal failure 
as the major risk factor for early mortality in adult patients with SCD (33). Intervention 
with ACE inhibitors, ARBs, and perhaps even hydroxyurea can reduce proteinuria and 
impede the progression of renal damage. Early detection of kidney damage by routine 
renal screens, therefore, has great clinical potential.  
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The first objective of this study was to evaluate if the SCD Program at BCH 
adhered to the NEPSCC guidelines. The NEPSCC guidelines suggested an annual renal 
screen in children at least five years of age. While the BCH department fell short of that 
goal, there are several factors which may have complicated our analysis.  First, patient 
compliance with physician orders may have played a complicating factor. At BCH, 
patients visit the outpatient laboratory for blood and urine specimen collection before or 
after their routine SCD clinic visit. Through chart review alone, it is impossible to 
distinguish between renal screens not performed because of poor patient compliance and 
renal screens not performed because of a provider’s failure to order or collect one. 
Secondly, pediatric patients are sometimes simply not able to void urine on demand. The 
difference between ordered renal screens at BCH and the recommendation by the 
NEPSCC may not be as large as the data suggests for completed screens.  
The second objective of the study was to determine if the performance of renal 
screens was influenced by certain patient demographics, specifically age, sex, sickle 
phenotype, and disease-modifying therapy. While the youngest age group (5-9 years old) 
tended to have a lower frequency of renal screens, this finding was not particularly 
surprising given that renal that renal abnormalities due to SCN become more common 
with increasing age (45-46). It is possible, therefore, that some providers are less likely to 
order renal screens for younger patients.  
Interestingly, the study found significant differences between the frequencies of 
renal screens performed within the male and female populations. The data suggests 
females are far more likely to have a renal screen performed during their routine clinic 
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evaluations than their male counterparts. This result is particularly surprising, as there is 
no proven or even perceived correlation between sex and the development of CKD (47-
49). It is possible, then, that this gender bias is predicated on clinical indications that are 
outside the scope of CKD and SCD, such as the role of gender in childhood intellectual 
and emotional development. Apart from a study that investigates BCH providers’ basis of 
practice, it would be useful to determine if this gender bias permeates across other sickle 
cell centers, or if it is exclusive to BCH.  
 While there were no statistically significant differences between the institutional 
average and the renal screen frequency within the three sickle phenotype subsets, the data 
does reveal some interesting variability. Patients with the sickle phenotype HbS Beta-
Zero tended to have less renal screens performed, and patients with the sickle phenotype 
HbS Beta-Plus tended to have more renal screens performed. Importantly, the 
populations in the HbS Beta-Zero and HbS Beta-Plus subsets were significantly smaller 
than the HbSS subset. The limited sample size in these particular cohorts likely skewed 
the data. Future studies may benefit from repeating this particular part of the investigation 
with a greater population of patients with the HbS Beta-Plus and HbS Beta-Zero 
phenotypes.    
The third objective of this study was to assess renal screen variability across BCH 
providers. The study found significant variability in the frequency with which renal 
screens are performed among providers. The validity of these findings, however, is 
limited by the small sample size of sickle cell visits for many of the attending physicians. 
Nearly half of the providers (13 of the 27) only oversaw 5 or less clinic visits that were 
 29 
 
“due” for a renal screen during the entire three-year study period. A study with more 
visits per provider or in which all providers saw the same number of SCD patients due for 
a renal screen would produce a more accurate assessment of provider variability. 
Interestingly, there was no significant difference between the frequency of MA 
and UA collection. Unlike MA excretion rates, UAs can help detect a number of 
disorders not necessarily related to proteinuria and CKD, such as diabetes, bladder 
infections and kidney stones (50). They are also fast and inexpensive to obtain and, 
perhaps most importantly, can be performed on the same urine specimen used to find MA 
excretion rates. This might explain why UA’s and MA excretion rates were obtained 
jointly in the majority of clinic visits where at least one test was performed. On the other 
hand, the data reveals a higher than expected frequency of UAs obtained in the absence 
of a MA excretion rate. UAs are far less accurate in detecting proteinuria and is a 
clinically inferior screening method compared to the measurement of MA excretion rate.  
Future investigations should further explore provider knowledge and beliefs. 
 
Future Research  
While this study describes the frequency of routine renal screens performed for 
SCD patients at BCH and its many affecting factors, it does little to elucidate the exact 
reasons behind why certain tests to detect renal dysfunction were performed at some 
visits and for some patients, but not for others. It would be of future interest, then, to 
develop a study that aims to profile providers’ beliefs, awareness of clinical guidelines, 
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and overall knowledge in order to provide insight into the influence of their decision 
making. 
Furthermore, this study can serve as a useful framework to guide future efforts to 
improve clinical practice. Further investigations should be conducted following 
interventions designed to increase routine renal screen performance at the sickle cell 
clinic. Such interventions might include provider education and the development of a 
laboratory order template for sickle cell clinic visits that includes a renal screen by 
microalbumin excretion rate.  
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